Innate Pharma

Paul Scherrer Institut

University of Genoa

Novo Nordisk A/s

Innate Pharma, S.a.

Innate Pharma S.a.s.

Sanofi

Centre Leon Berard

Novo Nordisk-a/s Novo Alle

Orega Biotech

Universita Di Genova

Orega Biotech Sas

Laurent Gauthier

Benjamin Rossi

Carine Paturel

Nadia Anceriz

Ivan Perrot

Ariane Morel

Roger Schibli

Christian Belmant

Delphine Bregeon

Patrick Dennler

Eliane Fischer

Yannis Morel

Alessandro Moretta

Nicolas Gourdin

Pascale Andre

Nicolas Schneider

Peter Andreas Nicolai Reumert Wagtmann

Mathieu Blery

Hélène Sicard

Stéphanie Cornen

Mariella Della Chiesa

François Romagne

Nicolai Wagtmann

Kristian Kjaergaard

Stefan Zahn

Anders Svensson

Ivan Svendsen

Angela Virone-Oddos

Stéphanie Chanteux

Marielle Chiron

Silvia Parolini

François Romagné

Agnes Tisserant

Karine Chemin

Michael Wilken

Simon Kollnberger

Stéphanie Zerbib

Nicolas Anfossi

Francois Romagné

Helene Sicard

Francois Romagne

Peter Andreas Wagtmann

Christophe Caux

Christine Menetrier-Caux

Søren Berg Padkær

Soren Berg Padkjaer

Cecile Bonnafous

Pieter Spee

Cécile Bonnafous

Alessandro Masiero

Matthias Thorolfsson

Ingo Focken

Yanfeng Zhou

Pieter Johannes Louis Spee

Leila Sevigny

Jochen Beninga

Sambasiva Rao

Matthias Thórólfsson

Søren Berg Padkjær

Soren Berg Padkaer

Catherine Massacrier

Alexandre Tang

Stephanie Zerbib

Stephanie Cornen

Agnès Tisserant

Eric Aubin

Søren Berg Padkaer

Soeren Berg Padkaer

Soeren Berg Padkjaer

Christine Menetrier-caux

The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.

NKp46 binding agents

Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Multispecific NK engager protein

The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

Humanized antibodies with increased stability

The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

Nucleic acids encoding and methods of producing proteins comprising antibody chains

The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).

Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering

This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

CD73 blockade

NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Variable regions for NKp46 binding proteins

The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

KIR3DL2 binding agents

NKp46 binding proteins

The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-&#x3b3; receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).

Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123

This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

Siglec-9-neutralizing antibodies

Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide

Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.

Multispecific antigen binding proteins

Growing community of inventors

Marseilles, France

Laurent Gauthier